- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04907708
Comparative Effects of Metformin and Insulin on Stereological Studies and Immunohistochemistry of Placenta
Comparative Studies of Metformin and Insulin on Stereological Studies and Immunohistochemistry of Placenta
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Diabetes mellitus is a group of metabolic disorder with relative or absolute deficiency of insulin. Pregnancy is a potentially glucose intolerant condition as insulin sensitivity decreases with the progress of pregnancy leading to the development of gestational diabetes mellitus (GDM). It is diagnosed in approximately 3-9% of pregnancies and is growing in prevalence. In Pakistan the recent prevalence of GDM is reported to be 3-3.45% but the complications are much higher due to poor glycemic control, lack of awareness and inadequate medical facilities. Placenta is an important feto-maternal organ which is responsible for nutrition of the fetus. It also provides the retrospective information regarding infant's prenatal development. Structurally, human placenta is a complex vascular organ that allows exchange of nutrients and chemicals between fetal and maternal blood. Proper development and maturity of placenta are strongly connected with fetal growth and survival.
GDM produces anatomical and physiological alterations in placenta. This can be related to altered levels of fetal insulin and multiple growth factors such as placental vascular endothelial growth factor (VEGF), Insulin like growth factors (IGF and IGF binding proteins) which regulate the fetal and placental development. Morphologically, diabetic placentae are larger in size and volume. Microscopically, diabetic placenta shows degenerative alternations such as villous fibrinoid necrosis, chorangiosis, villous immaturity, calcification and syncytial knots formation which show intense hypoxia of the placental tissues.
Nutritional therapy (diet control) is foremost important for achieving target glucose values during pregnancy but in uncontrolled cases pharmacological intervention is required. Parental Insulin is the traditional therapy in such circumstances, but is an expensive medication and is associated with high incidence of neonatal and maternal hypoglycemia, still births, neonatal morbidity and mortality. It is documented to produce many placental alterations such as immature villi, hemorrhages, edema, cystic changes and fibrinoid necrosis. It has been postulated that the reason behind all these hypoxic changes are the variation in the blood glucose level that occur in the maternal blood as sugar level suddenly dropped soon after Insulin injection and are at highest just before the next dose of Insulin.
The use of oral anti-diabetic medications such as Metformin in the management of gestational diabetes has increased over the past several years. Recent studies has established that Metformin can be a better option for GDM as it well controls glycemia (produces euglycemic) with good pregnancy outcomes. Metformin is an oral anti-diabetic drug from biguanide group; work by improving insulin sensitivity, reducing hepatic gluconeogenesis and also by increasing peripheral glucose uptake and utilization. It is now been upgraded to category B drug as is not associated with teratogenic effects. But what are the effects of Metformin on stereological morphometric study and immunochemistry of placental tissues were left to be evaluated. Stereology provides practical measurements and significant approach for obtaining quantitative estimates of small structures on histological slides. In placental tissue it is performed to obtain unbiased quantitative estimates of placental components that inform about development and also estimate of structural parameters that have direct influence on placental functional capacity. Immunohistochemistry or immunofluorescence of tissue sections also provide valuable insight to placental structure and protein expression with three-dimensional spatial information, including morphology that cannot be obtained on microscopy.
With this background knowledge, study was designed with the following objectives:
- To evaluate the placental gross and microscopic changes in normal, diet control, Metformin and Insulin treated in newly enrolled GDM females
- To evaluate stereological morphometric details of placenta in normal, diet control, Metformin and Insulin all enrolled females
- To evaluate immunohistochemistry of placental tissues in normal, diet control, Metformin and Insulin in all enrolled females
- To compare the placental morphology, stereology and immunohistochemistry with in the groups.
- To evaluate the fetal and maternal outcome in normal, diet control, Metformin and Insulin treated gestational diabetics.
- To correlate the placental morphology with the fetal and maternal outcome in Metformin and Insulin treated gestational diabetics
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Sindh
-
Karachi, Sindh, Pakistan, 75510
- Jinnah Post graduate Medical Centre
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
For this study placentae were collected from:
- Patients who were diagnosed as GDM during second trimester screening for FBS and RBS, confirmed further by OGCT and OGTT.
- GDM patients who signed the written informed consent.
- GDM patients who were in ages between 18 years and 40 years and had no other comorbid such hypertension, CVD etc
- Full term GDM patients with singleton pregnancy (37 weeks and above)
- GDM patients whose placenta were preserved within 30-40 minutes of delivery.
Exclusion Criteria:
Placentae were not collected from:
- GDM Patients with ages less than 18 or more than 40 years
- GDM females with some co-morbid and complications (e.g. hypertension, CVD, diabetes type 1 or diabetes type 2 before gestation, abnormal Urea Creatinine Electrolyte (UCE) and Liver function test (LFTs).
- GDM Patients who delivered pre-termed (< 37 weeks of gestation) or post termed (>42 weeks of gestation)
- GDM patients with twin pregnancy.
- GDM Patients if not preserved in the formalin properly within 30-40 minutes of delivery.
- GDM females who were given combined (Metformin and insulin) therapy.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Kein Eingriff: Normal healthy controls
females in second trimester with normal glucose levels
|
|
|
Kein Eingriff: Diet controlled
females in second trimester with blood sugar levels below 129mg/dl
|
|
|
Experimental: Metformin
females in second trimester with blood sugar levels above 130mg/dl treated with Metformin
|
Euglycemic agent
|
|
Experimental: Insulin
females in second trimester with blood sugar levels above 130mg/dl being treated with Insulin
|
Hypoglycemic agent
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Mean morphometric diffusion capacity for oxygen (MMDC) in placental tissues
Zeitfenster: 15 months
|
With detailed stereological assessment MMDC can be calculated for the placenta to visualize which group placenta allows better diffusion of oxygen
|
15 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of immuno-antigens present in placental tissue
Zeitfenster: 15 months
|
The percentage of immuno-antigens on the placental tissue is related to the hypoxic and vascular changes in the placenta.
|
15 months
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: KAUSER AAMIR, Ph.D, BMSI, JPMC,KARACHI
Publikationen und hilfreiche Links
Nützliche Links
- Belkacemi, L., Kjos, S., Nelson, D. M., & Desai, M. (2013). Reduced apoptosis in term placentas from gestational diabetic pregnancies. Journal of Developmental Origins of Health and Disease, 4 (3), 256-265.
- Casson, I. F., Clarke, C, A., Howard, C.V., McKendrick, O., Pennycook, S., Pharoah, P.O.D. (1997). Outcomes of pregnancy in insulin dependent diabetic women: results of a five-year population cohort study, British Medical Journal, 315, 275.
- The Incidence of Placental Abnormalities, Maternal and Cord Plasma Malondialdehyde and Vascular Endothelial Growth Factor Levels in Women with Gestational Diabetes Mellitus and No
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- UKarachi
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Metformin
-
Anji PharmaSuspendiertDiabetes mellitus, Typ 2Spanien, Vereinigte Staaten, Kanada, Ungarn, Brasilien, Tschechien, Polen, Bulgarien
-
ShionogiAbgeschlossen
-
NuSirt BiopharmaAbgeschlossenTyp 2 Diabetes mellitusVereinigte Staaten
-
Aspargo Labs, IncNoch keine RekrutierungGesunder Freiwilliger
-
Bristol-Myers SquibbAbgeschlossenTyp 2 Diabetes mellitusSüdafrika, Vereinigte Staaten, Kanada, Puerto Rico, Ungarn, Deutschland, Tschechien, Polen, Rumänien, Vereinigtes Königreich
-
Aspargo Labs, IncNoch keine Rekrutierung
-
Aspargo Labs, IncNoch keine Rekrutierung
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceAbgeschlossenTyp 2 Diabetes mellitus | Vor DiabetesAustralien
-
Charles University, Czech RepublicAbgeschlossen
-
Aspargo Labs, IncNoch keine Rekrutierung